150 related articles for article (PubMed ID: 35820850)
1. Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-up.
Clark PJ; Valery PC; Ward J; Strasser SI; Weltman M; Thompson A; Levy MT; Leggett B; Zekry A; Rong J; Angus P; George J; Bollipo S; McGarity B; Sievert W; Macquillan G; Tse E; Nicoll A; Wade A; Chu G; Harding D; Cheng W; Farrell G; Roberts SK
BMC Gastroenterol; 2022 Jul; 22(1):339. PubMed ID: 35820850
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of direct-acting antiviral therapy among Aboriginal and Torres Strait Islander peoples with HCV infection in Australia: A national real-world cohort (REACH-C).
Hudson-Buhagiar J; Carson J; Monaghan S; Collie P; Nelson R; Van Gessel H; Read P; Hanson J; Monaghan R; Matthews G; Dore GJ; Martinello M;
J Viral Hepat; 2023 May; 30(5):386-396. PubMed ID: 36651627
[TBL] [Abstract][Full Text] [Related]
3. Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort.
Clark PJ; Valery PC; Strasser SI; Weltman M; Thompson AJ; Levy M; Leggett B; Zekry A; Rong J; Angus P; George J; Bollipo S; McGarity B; Sievert W; Macquillan G; Tse E; Nicoll A; Wade A; Chu G; Harding D; Cheng W; Farrell G; Roberts SK
Dig Dis Sci; 2023 Jan; 68(1):291-303. PubMed ID: 35552941
[TBL] [Abstract][Full Text] [Related]
4. Broadening and strengthening the health providers caring for patients with chronic hepatitis C may improve continuity of care.
Clark PJ; Valery PC; Strasser SI; Weltman M; Thompson A; Levy MT; Leggett B; Zekry A; Rong J; Sinclair M; George J; Bollipo S; McGarity B; Sievert W; MacQuillan G; Tse E; Nicoll A; Wade A; Cheng W; Roberts SK
J Gastroenterol Hepatol; 2024 Mar; 39(3):568-575. PubMed ID: 38114452
[TBL] [Abstract][Full Text] [Related]
5. Characterizing the cascade of care for hepatitis C virus infection among Status First Nations peoples in Ontario: a retrospective cohort study.
Mendlowitz AB; Bremner KE; Krahn M; Walker JD; Wong WWL; Sander B; Jones L; Isaranuwatchai W; Feld JJ
CMAJ; 2023 Apr; 195(14):E499-E512. PubMed ID: 37040993
[TBL] [Abstract][Full Text] [Related]
6. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?
Christensen S; Buggisch P; Mauss S; Böker KHW; Schott E; Klinker H; Zimmermann T; Weber B; Reimer J; Serfert Y; Wedemeyer H
Addiction; 2018 May; 113(5):868-882. PubMed ID: 29359361
[TBL] [Abstract][Full Text] [Related]
7. Real-world outcomes of unrestricted direct-acting antiviral treatment for hepatitis C in Australia: The South Australian statewide experience.
Haridy J; Wigg A; Muller K; Ramachandran J; Tilley E; Waddell V; Gordon D; Shaw D; Huynh D; Stewart J; Nelson R; Warner M; Boyd M; Chinnaratha MA; Harding D; Ralton L; Colman A; Liew D; Iyngkaran G; Tse E;
J Viral Hepat; 2018 Nov; 25(11):1287-1297. PubMed ID: 29888827
[TBL] [Abstract][Full Text] [Related]
8. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.
Ji F; Yeo YH; Wei MT; Ogawa E; Enomoto M; Lee DH; Iio E; Lubel J; Wang W; Wei B; Ide T; Preda CM; Conti F; Minami T; Bielen R; Sezaki H; Barone M; Kolly P; Chu PS; Virlogeux V; Eurich D; Henry L; Bass MB; Kanai T; Dang S; Li Z; Dufour JF; Zoulim F; Andreone P; Cheung RC; Tanaka Y; Furusyo N; Toyoda H; Tamori A; Nguyen MH
J Hepatol; 2019 Sep; 71(3):473-485. PubMed ID: 31096005
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F
BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172
[TBL] [Abstract][Full Text] [Related]
10. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.
Read P; Lothian R; Chronister K; Gilliver R; Kearley J; Dore GJ; van Beek I
Int J Drug Policy; 2017 Sep; 47():209-215. PubMed ID: 28587943
[TBL] [Abstract][Full Text] [Related]
11. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
[TBL] [Abstract][Full Text] [Related]
12. A platform in the use of medicines to treat chronic hepatitis C (PLATINUM C): protocol for a prospective treatment registry of real-world outcomes for hepatitis C.
Ramsay J; Marsh J; Pedrana A; Andric N; Norman R; Cheng W; Webb S; Zeps N; Bellgard M; Graves T; Hellard M; Snelling T
BMC Infect Dis; 2020 Oct; 20(1):802. PubMed ID: 33121439
[TBL] [Abstract][Full Text] [Related]
13. Socio-economic factors associated with loss to follow-up among individuals with HCV: A Dutch nationwide cross-sectional study.
van Dijk M; Boyd A; Brakenhoff SM; Isfordink CJ; van Zoest RA; Verhagen MD; de Knegt RJ; Drenth JPH; van der Valk M;
Liver Int; 2024 Jan; 44(1):52-60. PubMed ID: 37718515
[TBL] [Abstract][Full Text] [Related]
14. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
[TBL] [Abstract][Full Text] [Related]
15. Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals.
Corma-Gómez A; Macías J; Téllez F; Freyre-Carrillo C; Morano L; Rivero-Juárez A; Ríos MJ; Alados JC; Vera-Méndez FJ; Merchante N; Palacios R; Granados R; Merino D; De Los Santos I; Pineda JA
Clin Infect Dis; 2020 Dec; 71(9):2354-2362. PubMed ID: 31754695
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.
Petta S; Adinolfi LE; Fracanzani AL; Rini F; Caldarella R; Calvaruso V; Cammà C; Ciaccio M; Di Marco V; Grimaudo S; Licata A; Marrone A; Nevola R; Pipitone RM; Pinto A; Rinaldi L; Torres D; Tuttolomondo A; Valenti L; Fargion S; Craxì A
J Hepatol; 2018 Jul; 69(1):18-24. PubMed ID: 29505844
[TBL] [Abstract][Full Text] [Related]
17. Sustained Virologic Response of Patients Hospitalized Compared With Those Not Hospitalized During Treatment for Hepatitis C Virus With Direct-Acting Antivirals.
Gentene AJ; Bell AM; Pence A; Thomas K; Jakubecz C; Stacy E; Woolf B; Guido MR; Mueller EW; Sherman KE
Ann Pharmacother; 2021 May; 55(5):565-574. PubMed ID: 33016095
[TBL] [Abstract][Full Text] [Related]
18. Real-world treatment outcome of direct-acting antivirals and patient survival rates in chronic hepatitis C virus infection in Eritrea.
Ghebremeskel GG; Berhe Solomon M; Achila OO; Mengistu ST; Asmelash RF; Berhane Mesfin A; Hamida ME
Sci Rep; 2023 Nov; 13(1):20792. PubMed ID: 38012181
[TBL] [Abstract][Full Text] [Related]
19. Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals.
Serper M; Evon DM; Stewart PW; Lok AS; Amador J; Reeve BB; Golin CE; Fried MW; Reddy KR; Sterling RK; Sarkar S; Di Bisceglie AM; Lim JK; Nelson DR; Reau N
J Gen Intern Med; 2020 Apr; 35(4):1011-1020. PubMed ID: 31659661
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with lost to follow-up after hepatitis C treatment delivered by primary care teams in an inner-city multi-site program, Vancouver, Canada.
Nouch S; Gallagher L; Erickson M; Elbaharia R; Zhang W; Wang L; Bacani N; Kason D; Kleban H; Knebel L; Hall D; Barrios R; Hull M
Int J Drug Policy; 2018 Sep; 59():76-84. PubMed ID: 30048877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
